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Abstract
Background: L-2-hydroxyglutaric aciduria (L2HGA) is a progressive neurometabolic disease of brain caused by mutations
of in L-2-hydroxyglutarate dehydrogenase (L2HGDH) gene. Cardinal clinical features include cerebellar ataxia, epilepsy,
neurodevelopmental delay, intellectual disability, and other clinical neurological deficits.
Case presentation: We describe an index case of the family presented with generalised tonic-clonic seizure,
developmental delay, intellectual disability, and ataxia. Initially, the differential diagnosis was difficult to be established
and a SNP genome wide scan identified the candidate region on chromosome 14q22.1. DNA sequencing showed a
novel homozygous mutation in the candidate gene L2HGDH (NM_024884.2: c.178G > A; p.Gly60Arg). The mutation p.
Gly60Arg lies in the highly conserved FAD/NAD(P)-binding domain of this mitochondrial enzyme, predicted to disturb
enzymatic function.
Conclusions: The combination of homozygosity mapping and DNA sequencing identified a novel mutation in
Pakistani family with variable clinical features. This is second report of a mutation in L2HGDH gene from Pakistan
and the largest family with L2HGA reported to date.
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Background
L-2-hydroxyglutaric aciduria (L2HGA) is a rare auto-
somal recessive neurodegenerative disorder of metabol-
ism [OMIM #236792] which is due to the accumulation
of L-2-hydroxyglutaric acid (LGA) in urine, plasma and
cerebrospinal fluid (CSF) [1, 2]. The phenotypic features
of this organic aciduria are diverse, including develop-
mental delay, cerebellar ataxia, epilepsy, severe intellec-
tual disability, and macrocephaly [3–5]. The onset of
disease has been reported to occur at an early age with
severe epileptic fits or neurodegenerative symptoms, al-
though it may also appear in adulthood with less severe
presentations. There are reports of increased incidence
of the development of brain tumours due to progression
in L2HGA [6–9].
The diagnosis of L2HGA comprises of biochemical,
radiological and genetic testing. The MRI abnormalities
seen in the subcortical cerebral white matter, putamen,
caudate nucleus, globus pallidus, and dentate nucleus
are unique to L2HGA, and are used as baseline investi-
gation [6, 10–16]. The disease-causing gene is L-2-
hydroxyglutarate dehydrogenase (L2HGDH-NM_024884.2)
which is located on chromosome 14q22.1 [MIM 609584]
and comprises of 10 coding exons spanning 75 kb. It is
expressed in various tissues with the highest expression
found in the brain [15, 17]. The gene encodes a protein of
463 amino acids, specifying a mitochondrial targeting
sequence (aa 1-50) and a domain for family of FAD-
dependent enzymes [15]. L2HGDH is a mitochondrial en-
zyme which catalyses oxidation of L-2-hydroxyglutarate
(L2HG) to α2-ketoglutarate (α2KG); a metabolic product
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bound to mitochondrial membrane [15, 17]. Several
mutations L2HGDH have been reported worldwide in
affected individuals belonging to various ethnic groups
[6, 8, 13–16, 18, 19] (http://grenada.lumc.nl/LOVD2/
vumc/status.php) [17].
The present case describes the clinical presentation
and mutation analysis of L2HGDH in a large Pakistani
consanguineous family comprising multiple individuals
affected by a metabolic neurological disorder. Homozy-
gosity and sequencing studies revealed a rare missense
mutation (NM_024884.2:c.178G > A; p.Gly60Arg), in
exon 2 of L2HGDH as the likely cause of disease in this
family.
Case presentation
A 16 year old girl (IV-4) presented to hospital with
history of seizures since the age of 8 months, intellec-
tual delay, and ataxia. At the age of 13 years she was
described by parents as ‘mentally dull’ and generalized
tonic-clonic seizures recurred with increased fre-
quency, mostly at night. Her elder sister (IV-6) and
brother (IV-1) also showed symptoms of epilepsy and
intellectual delay, as did three first cousins (IV-8, IV-
9, and IV-10) although no in depth clinical evaluation
was performed.
Clinical evaluation of index case
On physical and clinical examination IV-4 was alert,
with an ataxic gait. Manual muscular testing did not
note any weakness of limbs, but mild finger and nose
ataxia was apparent along with a retarded capability of
speech. Her deep tender reflexes were +++ and symmet-
rically preserved, while the plantar responses were bilat-
erally flexor. Her brain MRI showed abnormal diffuse T2
hyperintense signals in the subcortical white matter and
bilateral symmetrical T2 hyperintense signals in bilateral
basal ganglia (Fig. 1). Mild cortical cerebellar atrophy
was also seen. Electroencephalogram (EEG) examination
showed moderate diffuse encephalopathy/moderate dif-
fuse brain dysfunction and observed epileptiform activity
arising from the right hemisphere (Fig. 1). Urine testing
for L2-hydroxyglutarate was not possible due to unavail-
ability of this test in regional diagnostic laboratories, and
remote setting of the family involved. Genetic investiga-
tion was recommended and she was advised for tablet
Neurobion 1 BD, tablet Folic acid 5 mg OD, capsule Co-
enzyme Q-10, 50 mg BD, tablet Loprin 75 mg for symp-
tomatic management.
Molecular genetic analysis
Genomic DNA was extracted from peripheral blood
samples. Due to the availability of multiple affected
Fig. 1 Clinical features of individuals homozygous for L2HGDH c.178G > A. Patient VI:4 at 16 years of age, showed diffuse T2 hyperintense signals
abnormality in the subcortical white matter (a), bilateral symmetrical T2 hyperintense signals in bilateral basal ganglia (b) and cerebellar atrophy
(c) and epileptiform changes in EEG (d)
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family members and the consanguinity of the parents of
the index case (Fig. 1a), autozygosity mapping through
genome-wide SNP genotyping was conducted as previ-
ously described using Illumina Human CytoSNP-12 v2.1
microarrays [20]. A 24.5 Mb homozygous region on
chromosome 14 (chr14:36,976,285-61,626,155 [hg38])
shared among all affected individuals delimited by re-
combinant SNP markers rs10483479 and rs2244057.
The disease locus was predicted to contain 327 genes in-
cluding L2HGDH [MIM: 236,792], previously implicated
in causing overlapping neurological phenotypes. Subse-
quent di-deoxy sequence analysis of exon 2 (amplicon
size 891 bp; primers: 5’-CCAATACATTGCTCTGT
CGC-3′; 5’-AAAGTGAGCACAATCCTGGG-3′; Cyc-
ling conditions: Denaturation at 95 °C for 2 min; 2 cycles
of 30 s at 95 °C, 30 s at 66 °C, 30 s at 72 °C; 2 cycles of
30 s at 95 °C, 30 s at 64 °C, 30 s at 72 °C; 35 cycles of
30 s at 95 °C, 30 s at 62 °C, 30 s at 72 °C and a final ex-
tension of 2 min at 72 °C) revealed a rare/novel missense
variant with a single heterozygous individual of South
Asian origin reported in 60,680 samples by the ExAC
Consortium (http://exac.broadinstitute.org/variant/14-
50769698-C-T; rs771556952; NM_024884.2:c.178G > A;
p.Gly60Arg), which was found to co-segregate in the
extended pedigree. The variant was not present in 150
chromosomes of Pakistani ancestry.
Computational analysis
Amino acid sequence alignment using the program Clus-
talW 2.1 showed high conservation of the Gly60 residue
in related vertebrates (Fig. 2). The variant alters a strin-
gently conserved amino acid residue and is predicted to
be highly damaging by standard prediction programs
using the Emsembl Variant Effect Predictor web interface
(FATHMM score = − 6.21 (Damaging); MutationTaster
score = 1 (Disease causing); PolyPhen2 score (HumDiv) = 1
(Probably damaging); PolyPhen2 score (HumVar) = 1
(Probably damaging); PROVEAN score = − 7.46 (Dam-
aging); SIFT score = 0 (Deleterious)).
On structural analysis, the Gly60 residue of L2HGDH
resides in the helix region. This short non-polar glycine
residue is replaced in the mutant protein by the larger,
more positively charged and hydrophilic arginine resi-
due. The Gly60Arg mutation is predicted to produce a
minor local conformational change due to the difference
in the observed contacts and surface area. The native
glycine residue is only involved in intermolecular inter-
actions with threonine at position 90 while the replaced
Fig. 2 Family pedigree showing L2HGDH c.178G > A genotype data and images of affected individuals. a Simplified pedigree of the extended
Pakistani family investigated, with pictorial representation of genotypes across ∼24 Mb of chromosome 14 encompassing the disease locus
(dashed blue boxed region, red boxed region). All affected individuals were subsequently shown to be homozygous for the L2HGDH variant
NM_024884.2:c.178G > A (indicated). Parental samples were heterozygous, and unaffected siblings were either WT or heterozygous carriers. b-d
Electropherograms showing the DNA sequence at the position of L2HGDH c.178G > A in a homozygous affected (b), heterozygous father (c) and
WT control (d) and amino acid alignment using ClustalW showing high conservation of the G60 residue across vertebrates (e)
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basic arginine introduces an electrically charged, basic
guanidium group which, unlike glycine, has more hydro-
gen bonding capabilities leading to the formation of an a
inter molecular hydrogen bond with Thr90 as well as
with Arg196 and Thr195. This leads to a slight local per-
turbation of the helix conformation for mutated protein
(Fig. 3).
Discussion and conclusions
In this study, we describe a large pedigree from Pakistan
showing multiple neurological symptoms. Homozygosity
mapping and Sanger sequencing revealed a novel mis-
sense mutation in L2HGDH gene. This is the second
report of L2HGDH mutation in a Pakistani family; previ-
ously a nonsense mutation (p.Arg335Ter) was reported
in a family showing a neuro-degenerative disorder of
metabolism with two affected individuals [8]. Clinical
and radiologic examinations of affected individuals iden-
tified presence of a slowly progressive neurodegenerative
disease with cerebellar ataxia, seizures, delay in growth
and abnormal subcortical white matter. MRI showed the
persistent changes in the subcortical white matter char-
acteristic in L2HGA leukoencephalopathy while the
brain stem involvement in other leukoencephalopathy
[11, 15]. Although additional phenotypic characteristics
are described in the literature, including macrocephaly,
pyramidal and extra-pyramidal features, these were not
present in our patients, [15, 21].
L2HGDH encodes L-2 hydroxyglutare dehydrogenase
which is the key contributor for this neurodegenerative
disease. A large number of families and cases are re-
ported with more than 100 pathogenic mutations in this
gene. These mutations are mostly repeated in different
ethnic populations. Interestingly, the disease is mostly
reported in families from Mediterranean origin with nu-
merous families reported from Turkey, Tunisia, Italy and
Lebanon [6, 8, 15, 17]. Currently, there are 162 families
with 283 cases which have been investigated for muta-
tions in L2HGDH gene comprising a total of 112 muta-
tions, 36 of which are found repeatedly found in
different ethnic groups (http://grenada.lumc.nl/LOVD2/
vumc/status.php).
The possible impact of our mutation on protein func-
tion was investigated using in silico bioinformatics tools.
The mutation was predicted to affect the hydrogen
bonding, and thus alter the stereochemistry of the pro-
tein (Fig. 3) [22].
To conclude, this case report provides the molecular
diagnosis of a large consanguineous Pakistani family
with six individuals. We identified a novel L2HGDH mu-
tation predicted to cause in a loss of stability of
L2HGDH protein.
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